Kynurenic acid - BirchBioMed

Drug Profile

Kynurenic acid - BirchBioMed

Alternative Names: Fibrostop; Fibrostop 2; FS 2

Latest Information Update: 19 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of British Columbia
  • Developer BirchBioMed; University of British Columbia
  • Class Antiepileptic drugs; Antifibrotics; Hydroxyquinolines; Muscle relaxants; Neuroprotectants; Small molecules
  • Mechanism of Action Connective tissue growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Scars

Most Recent Events

  • 16 Feb 2018 Health Canada approves phase II clinical trial application for kynurenic acid in Scars
  • 16 Feb 2018 BirchBioMed plans a phase II trial for Scars in Canada
  • 31 Aug 2016 BirchBioMed completes a phase I trial in Scars (In volunteers) in canada (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top